Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioVersys AG's book value per share for the quarter that ended in Dec. 2025 was CHF10.23.
During the past 12 months, BioVersys AG's average Book Value Per Share Growth Rate was 466.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
BioVersys AG's current price is CHF27.00. Its book value per share for the quarter that ended in Dec. 2025 was CHF10.23. Hence, today's PB Ratio of BioVersys AG is 2.64.
During the past 2 years, the highest P/B Ratio of BioVersys AG was 2.64. The lowest was 0.00. And the median was 0.00.
BioVersys AG (XSWX:BIOV) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
BioVersys AG Book Value per Share Related Terms
BioVersys AG Book Value per Share Historical Data
* Premium members only.
The historical data trend for BioVersys AG's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG Book Value per Share Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
Book Value per Share
1.81
10.23
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
Book Value per Share
0.00
1.81
11.97
10.23
XSWX:BIOV vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, BioVersys AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioVersys AG's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of CHF10.23 mean?
BioVersys AG (XSWX:BIOV) has a Book Value per Share of CHF10.23 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Book Value per Share too high?
BioVersys AG's current Book Value per Share is CHF10.23. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Book Value per Share compare to VRTX and REGN?
BioVersys AG's Book Value per Share of CHF10.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on BioVersys AG and its competitors. BioVersys AG's current Book Value per Share is CHF10.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Book Value per Share of CHF10.23. The current Book Value per Share is CHF10.23. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Book Value per Share is CHF10.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score
Get the complete analysis for XSWX:BIOV
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIOV has been successfully added to your 
